Selected ASCO Abstracts

  • Hatch, AJ, Ou, F, Zemla, T, Starr, MD, Brady, JC, Liu, Y, Innocenti, F, Meyerhardt, JA, O’Reilly EM, Lenz, H, Hurwitz, H, Venook, AP, Nixon, AB.  On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80404 (Alliance). J Clin Oncol 37, 2019 (suppl 4; abstr 588).  https://meetinglibrary.asco.org/record/169026/abstract

 

  • Liu, Y, Burdett, K, Starr, MD, Brady, JC, Hatch, AJ, Ivanova, A, Moore, DT, Hammond, K, Lee, MS, O’Neil, B, Innocenti, F, Owzar, K, Sanoff, HK, Nixon, AB.  Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029. J Clin Oncol 37, 2019 (suppl 4; abstr 587). https://meetinglibrary.asco.org/record/169034/abstract

 

  • Buechel, AM, Enserro, D, Burger, RA, Brady, MF, Wade, K, Secord, AA, Nixon, AB, Mirniaharikandehei, S, Liu, H, Zheng, B, Gray, H, Tewari, KS, O’Malley, DM, Mannel, RS, Moore, KN, Birrer, MJ. Correlation of imaging and plasma-based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC): A GOG 218 ancillary data analysis. J Clin Oncol 36, 2018 (suppl; abstr 5507).  (Oral Presentation). https://meetinglibrary.asco.org/record/161670/abstract

 

  • Das, RK, Furchtgott, L, Meyerhardt, JA, Nixon, AB, Innocenti, F, Cunha, D, Rich, K, Lenz, H-J, Niedzwiecki, D, O’Reilly, EM, Ou, F-S, Latourelle, J. Wuest, D, Hayete, B, Khalil, I, and Venook, AP. Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).  J Clin Oncol 36, 2018 (suppl; abstr 3570).  https://meetinglibrary.asco.org/record/158938/abstract

 

  • Furchtgott, L, Swanson, D, Hayete, B, Khalil, I, Wuest, D, Rich, K,Nixon, AB, Niedzwiecki, D, Meyerhardt, JA, O’Reilly, EM, Ou, FS, Lenz, JH, Innocenti, F, Venook, AP. Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side. J Clin Oncol 35, 2017 (suppl; abstr 3528).  https://meetinglibrary.asco.org/record/148394/abstract

 

  • Sinicrope, FA, Ou, FS, Shi, Q, Nixon, AB, Mody, K, Levasseur, A, Dueck, AC, Dhanarajan, AR, Lieu, CH, Cohen, DJ, Innocenti, F, Behrens, RJ, Peters, W, Sargent, DJ, Sommer, N, O’Reilly, EM, Meyerhardt, J. Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502). J Clin Oncol 35, 2017 (suppl; abstr TPS3630).  https://meetinglibrary.asco.org/record/153089/abstract

 

  • George, DJ, Halabi, S, Starr, MD, Hurwitz, HI, Brady, JC, Barak, I, Morris, MJ, Rini, BI, Small, EJ, Kim, W, Taplin, ME, Nixon AB. Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance). J Clin Oncol 35, 2017 (suppl; abstr 4522). (Poster Discussion). https://meetinglibrary.asco.org/record/144710/abstract

 

  • Liu, Y, Yuan, Z, Dadong, Z, Starr, MD, Brady, JC, Jivani, MA, Adams, BJ, Alvarez, D, Attia, S, Choueiri, TK, Theuer, CP, Owzar, K, Hurwitz, H, and Nixon, AB. Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy. J Clin Oncol 35, 2017 (suppl; abstr 11546).  https://meetinglibrary.asco.org/record/146164/abstract

 

  • AB. Nixon, A. Sibley, A.J. Hatch, Y. Liu, C.Jiang, F. Mulkey, M.D. Starr, J.C. Brady, D. Niedzwiecki, F. Innocenti, A.P. Venook, H.S. Hochster, H.J. Lenz, B.H. O’Neil, K. Owzar, H.I. Hurwitz. Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or bev plus Cetux: Results from CALGB 80405 (Alliance). J Clin Oncol 34, 2016 (suppl; abstr 3597).  https://meetinglibrary.asco.org/record/123660/abstract

 

  • Secord, D. Tritchler, Y. Liu, M.D. Starr, J.C. Brady, H.A. Lankes, H.I. Hurwitz, R.S. Mannel, K.S. Tewari, D.M. O’Malley, H.J. Gray, J.N. Bakkum-Gamez, K.Fujiwara, M. Boente, W. Deng, R.A. Burger, M.J. Birrer, A.B. Nixon. Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.J Clin Oncol 34, 2016 (suppl; abstr 5521). (Poster Discussion).  https://meetinglibrary.asco.org/record/125369/abstract

 

  • F. Seligmann, F. Elliott, B. Jacobs, A.J. Hatch, A. Sibley, S. Richman, C. Jiang, J. Barrett, K. Owzar, P. Quirke, H. Hurwitz, M.T. Seymour, A.B. Nixon. HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC).J Clin Oncol 33, 2015 (suppl; abstr 3583). https://meetinglibrary.asco.org/record/112002/abstract

 

  • J. Hatch, H. Pang, M.D. Starr, H.L. Kindler, E.M. O’Reilly, F. Innocenti, A.P. Venook, H.I. Hurwitz, A.B. Nixon. Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance). J Clin Oncol 32:5s, 2014 (suppl; abstr 11022). (Poster Discussion)  https://meetinglibrary.asco.org/record/89632/abstract

 

  • M. Kluger, S.Halabi, N.C. Solomon, L. Jilaveanu, C. Zito, J. Sznol, A.B. Nixon, B.I. Rini, E.J. Small, D.G. George. Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206. J Clin Oncol 32:5s, 2014 (suppl; abstr 4532). https://meetinglibrary.asco.org/record/95961/abstract

 

  • Cushman, S.M., Jiang, C., Shterev, I., Mahoney, M., Niedzwiecki, D., Mayer, R., Venook, A., Owzar, K., Hurwitz, H.I., and Nixon, A.B.  Tumor Markers of Efficacy and Resistance to Cetuximab (C) Treatment in Metastatic Colorectal Cancer (mCRC): Results from CALGB 80203 (Alliance) J Clin Oncol. 2013;31:Suppl; abstr 11011. (Oral Presentation). https://meetinglibrary.asco.org/record/86912/abstract

 

  • AB. Nixon, S. Halabi I. Shterev, M.D. Starr, J.C Brady, J. Dutcher, J. Hopkins, H.I. Hurwitz, E. Small, B. Rini, P.G. Febbo, D. George.  Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) +/- bevacizumab (B): Results from CALGB 90206 (Alliance) J Clin Oncol. 2013;31:Suppl; abstr 4520. (Poster Discussion).  https://meetinglibrary.asco.org/record/82014/abstract

 

  • AB. Nixon, H. Pang, M. Starr, D. Hollis, P. N. Friedman, M. M. Bertagnolli, H. L. Kindler, R. M. Goldberg, A. P. Venook, H. Hurwitz.  Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303. J Clin Oncol 2011;29:10508 (suppl; abstr ). (Oral Presentation). https://meetinglibrary.asco.org/record/82014/abstract